Education
About Us
Working with TipRanks
Follow Us
Jagsonpal Pharmaceuticals Ltd. (IN:JAGSNPHARM)
:JAGSNPHARM
JAGSNPHARM Stock Chart & Stats
₹193.50
-₹13.50(-5.18%)
At close: 4:00 PM EST
₹193.50
-₹13.50(-5.18%)
Day’s Range― - ―
52-Week Range₹154.90 - ₹301.80
Previous CloseN/A
Volume94.85K
Average Volume (3M)3.85K
Market Cap
₹11.30B
Enterprise Value₹11.24B
Total Cash (Recent Filing)₹1.29B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)27.5
Beta1.33
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)1.64
Shares Outstanding66,890,450
10 Day Avg. Volume3,534
30 Day Avg. Volume3,854
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)6.09
Price to Sales (P/S)5.44
P/FCF Ratio26.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetLow leverage and a high equity ratio provide durable financial stability. An equity-funded asset base reduces refinancing risk, supports capital allocation for growth or R&D, and gives the company flexibility to withstand sector cyclicality over the next several quarters.
Healthy Revenue And MarginsConsistent revenue expansion combined with healthy gross and net margins and improving EBIT/EBITDA indicates effective pricing and cost control. This underpins sustainable profitability, funding reinvestment and supporting long-term operational resilience in branded formulations.
Positive Cash GenerationStrong operating cash conversion demonstrates the business turns earnings into cash, enabling reinvestment, capex and shareholder returns without over-reliance on external funding. Solid cash generation supports strategic investments and steadier operations across cycles.
Bears Say
Declining Cash ReservesA reduction in cash and short-term investments erodes the company’s liquidity buffer. Over a 2–6 month horizon this can constrain working capital, limit flexibility to pursue organic or inorganic opportunities, and increase reliance on external financing in stress scenarios.
Earnings Per Share ContractionA meaningful decline in EPS growth signals weakening per-share profitability. Persisting EPS contraction can reflect margin pressure, higher costs, or dilution, and may reduce capacity to raise dividends or internally fund growth, weakening long-term shareholder returns.
Volatile Free Cash Flow GrowthInconsistent free cash flow growth complicates multi-quarter planning for capex, R&D and dividends. Variability increases forecasting uncertainty, can force stop-start investment cycles, and raises the risk that strategic initiatives are delayed or underfunded in weaker quarters.
Jagsonpal Pharmaceuticals Ltd. News
JAGSNPHARM FAQ
What was Jagsonpal Pharmaceuticals Ltd.’s price range in the past 12 months?
Jagsonpal Pharmaceuticals Ltd. lowest stock price was ₹154.90 and its highest was ₹301.80 in the past 12 months.
What is Jagsonpal Pharmaceuticals Ltd.’s market cap?
Jagsonpal Pharmaceuticals Ltd.’s market cap is ₹11.30B.
When is Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date?
Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date is May 26, 2026 which is in 85 days.
How were Jagsonpal Pharmaceuticals Ltd.’s earnings last quarter?
Jagsonpal Pharmaceuticals Ltd. released its earnings results on Jan 21, 2026. The company reported ₹1.64 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.64.
Is Jagsonpal Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Jagsonpal Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Jagsonpal Pharmaceuticals Ltd. pay dividends?
Jagsonpal Pharmaceuticals Ltd. pays a Annually dividend of ₹2.5 which represents an annual dividend yield of 1.24%. See more information on Jagsonpal Pharmaceuticals Ltd. dividends here
What is Jagsonpal Pharmaceuticals Ltd.’s EPS estimate?
Jagsonpal Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jagsonpal Pharmaceuticals Ltd. have?
Jagsonpal Pharmaceuticals Ltd. has 66,890,450 shares outstanding.
What happened to Jagsonpal Pharmaceuticals Ltd.’s price movement after its last earnings report?
Jagsonpal Pharmaceuticals Ltd. reported an EPS of ₹1.64 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.029%.
Which hedge fund is a major shareholder of Jagsonpal Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:JAGSNPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.
Technical Analysis
Bajaj Healthcare Ltd
―
Bliss Gvs Pharma Limited
―
Hester Biosciences Limited
―
Lincoln Pharmaceuticals Ltd
―
Themis Medicare Limited
―